Profit ratio

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Update by StockNews.com

Vanda Pharmaceuticals (NASDAQ: VNDA – Get a rating) has been upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report released on Friday.

Other stock analysts have also recently released reports on the company. Jefferies Financial Group upgraded Vanda Pharmaceuticals from a “buy” rating to a “hold” rating and lowered its price target for the stock from $24.00 to $12.00 in a Friday, February 25 report. TheStreet downgraded shares of Vanda Pharmaceuticals from a “b-” rating to a “c” rating in a report on Wednesday, February 9. To finish, Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a Thursday, May 12, report.

Shares of NASDAQ VNDA traded at $0.23 in Friday’s midday session, hitting $10.15. The company had a trading volume of 395,475 shares, compared to an average volume of 549,490. The company has a market capitalization of $573.37 million, a price-earnings ratio of 31.72 and a beta of 0, 60. Vanda Pharmaceuticals has a 12-month low of $9.24 and a 12-month high of $21.86. The company has a 50-day simple moving average of $10.55 and a two-hundred-day simple moving average of $13.11.

(A d)

What is the most productive stock you have ever owned? Dividends from these stocks have grown so rapidly over the years that they now earn us an average of 26%!

When you start getting paid 26% on your money, your financial troubles tend to evaporate.

Vanda Pharmaceuticals (NASDAQ: VNDA – Get a rating) last released its quarterly earnings data on Thursday, May 5. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.10). The company posted revenue of $60.19 million in the quarter, compared to $58.00 million expected by analysts. Vanda Pharmaceuticals had a net margin of 6.79% and a return on equity of 3.65%. In the same period of the previous year, the company had earned earnings per share of $0.15. Research analysts expect Vanda Pharmaceuticals to post 0.3 earnings per share for the current fiscal year.

Separately, director Richard W. Dugan sold 6,500 shares of the company in a transaction that took place on Tuesday, May 31. The shares were sold at an average price of $9.85, for a total value of $64,025.00. Following the completion of the sale, the administrator now directly owns 68,387 shares of the company, valued at $673,611.95. The transaction was disclosed in a legal filing with the SEC, which is available via the SEC website. 6.10% of the shares are held by insiders.

Institutional investors and hedge funds have recently been buying and selling stocks. LSV Asset Management increased its position in Vanda Pharmaceuticals by 6.2% in the 4th quarter. LSV Asset Management now owns 2,260,482 shares of the biopharmaceutical company worth $35,467,000 after purchasing an additional 131,385 shares during the period. Citigroup Inc. increased its stake in shares of Vanda Pharmaceuticals by 62.7% in the fourth quarter. Citigroup Inc. now owns 151,874 shares of the biopharmaceutical company valued at $2,383,000 after buying an additional 58,518 shares last quarter. Franklin Resources Inc. purchased a new stake in Vanda Pharmaceuticals stock during Q3 valued at approximately $546,000. Profit Investment Management LLC increased its position in Vanda Pharmaceuticals by 204.6% during the 4th quarter. Profit Investment Management LLC now owns 238,060 shares of the biopharmaceutical company worth $3,735,000 after acquiring an additional 159,906 shares last quarter. Finally, Barclays PLC increased its stake in Vanda Pharmaceuticals by 67.6% in the third quarter. Barclays PLC now owns 56,802 shares in the biopharmaceutical company worth $974,000 after acquiring an additional 22,912 shares during the period. 97.25% of the shares are held by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile (Get a rating)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, is focused on developing and commercializing therapies to address unmet medical needs. The Company’s marketed products include HETLIOZ for the treatment of non-24 hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

See also

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Vanda Pharmaceuticals right now?

Before you consider Vanda Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off… and Vanda Pharmaceuticals was not on the list.

Although Vanda Pharmaceuticals currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here